US FDA's expedited access plan for devices a 'program with no downside'?
This article was originally published in SRA
Executive Summary
Stakeholders appear unanimous in their support of a new plan by the US Food and Drug Administration to fast-track certain high-risk, high-value medical devices through the premarket approval (PMA) program.
You may also be interested in...
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024
Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.